BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th. Check Out Our […]

Related Keywords

, First Advisors Inc , Biolinerx Ltd , Allen Mooney Barnes Investment Advisors , B Riley Wealth Advisors Inc , Biolinerx Company Profile , Asset Management Corp , Rathbones Group , Get Free Report , Management Corp , First Advisors , Barnes Investment Advisors , Wealth Advisors , Riley Wealth Advisors , Linerx Ltd , Biolinerx Daily , Biolinerx , Nasdaq Blrx , Blrx , Medical , Upgrade , Stocknews Com ,